Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2010 5
2011 5
2012 18
2013 19
2014 29
2015 25
2016 25
2017 25
2018 38
2019 44
2020 36
2021 51
2022 65
2023 40
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Results by year

Filters applied: . Clear all
Page 1
Dacomitinib.
[No authors listed] [No authors listed] 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643328 Free Books & Documents. Review.
Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mutations in the epidermal growth factor receptor gene (EGFR). Dacomitinib is associated with high rate of transient serum aminotransfe …
Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mu …
Dacomitinib.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30372001 Free Books & Documents. Review.
No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of …
No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasm …
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Wu YL, et al. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958502 Clinical Trial.
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. ...Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib. Two treatment-related deaths occurr …
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. ...Treatment-related serious adverse eve …
Dacomitinib: First Global Approval.
Shirley M. Shirley M. Drugs. 2018 Dec;78(18):1947-1953. doi: 10.1007/s40265-018-1028-x. Drugs. 2018. PMID: 30506139 Review.
Dacomitinib (Vizimpro()) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours. ...Registration applications for the use of dacomitinib as first-line treatm …
Dacomitinib (Vizimpro()) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was deve …
Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Sun H, Wu YL. Sun H, et al. Future Oncol. 2019 Aug;15(23):2769-2777. doi: 10.2217/fon-2018-0535. Epub 2019 Aug 12. Future Oncol. 2019. PMID: 31401844 Review.
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to other TKIs. In the ARCHER 1050 trial, progression-free survival was improved by dacomitinib …
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR/Her1, Her2 and H …
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM, Batra U, Mok TSK, Loong HH. Lau SCM, et al. Drugs. 2019 Jun;79(8):823-831. doi: 10.1007/s40265-019-01115-y. Drugs. 2019. PMID: 31069718 Review.
Dacomitinib has not demonstrated any benefit in unselected patients with non-small-cell lung cancer, and its use should be limited to those with known EGFR-sensitizing mutations. Dacomitinib is associated with increased toxicities of diarrhea, rash, stomatitis, and …
Dacomitinib has not demonstrated any benefit in unselected patients with non-small-cell lung cancer, and its use should be limited to …
Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM, Sánchez-Gómez P, Vaz Salgado MÁ, Gargini R, Balañá C. Sepúlveda JM, et al. Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225. Epub 2018 Oct 5. Expert Opin Investig Drugs. 2018. PMID: 30247945 Review.
Dacomitinib has noteworthy antiglioma activity in preclinical models and has been tested in one phase II trial in patients with recurrent GB with EGFR amplification. Expert opinion: Despite the poor global results of Dacomitinib in recurrent GB shown in a phase II t …
Dacomitinib has noteworthy antiglioma activity in preclinical models and has been tested in one phase II trial in patients with recur …
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Mok TS, et al. Drugs. 2021 Feb;81(2):257-266. doi: 10.1007/s40265-020-01441-6. Drugs. 2021. PMID: 33331989 Free PMC article. Clinical Trial.
BACKGROUND: ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) and an EGFR-activating mutation, reported significant improvement in overall survival ( …
BACKGROUND: ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patie …
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
Santarpia M, Menis J, Chaib I, Gonzalez Cao M, Rosell R. Santarpia M, et al. Expert Rev Clin Pharmacol. 2019 Sep;12(9):831-840. doi: 10.1080/17512433.2019.1649136. Epub 2019 Aug 5. Expert Rev Clin Pharmacol. 2019. PMID: 31356117 Review.
Introduction: Different EGFR tyrosine kinase inhibitors (TKIs) are currently approved for the first-line treatment of NSCLC patients with EGFR mutations. Dacomitinib is an orally administered, second-generation pan-HER inhibitor that has shown to improve PFS and OS compare …
Introduction: Different EGFR tyrosine kinase inhibitors (TKIs) are currently approved for the first-line treatment of NSCLC patients with EG …
Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T, Tachihara M, Nishimura Y. Nagano T, et al. Drugs Today (Barc). 2019 Apr;55(4):231-236. doi: 10.1358/dot.2019.55.4.2965337. Drugs Today (Barc). 2019. PMID: 31050691 Review.
Dacomitinib represents a powerful new treatment option compared with first-generation EGFR-TKIs. In this paper, we review the clinical and preclinical studies of dacomitinib and discuss the drug's clinical value....
Dacomitinib represents a powerful new treatment option compared with first-generation EGFR-TKIs. In this paper, we review the clinica …
385 results